# Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy

> **NCT06528015** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Gang Xu** · enrollment: 206 (estimated)

## Conditions studied

- Glomerulonephritis, IGA
- Probiotics
- Budesonide

## Interventions

- **DRUG:** probiotics combined with enteric-coated budesonide capsule
- **DRUG:** probiotics placebo combined with enteric-coated budesonide capsules

## Key facts

- **NCT ID:** NCT06528015
- **Lead sponsor:** Gang Xu
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 206 (ESTIMATED)
- **Last updated:** 2024-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06528015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06528015, "Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06528015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*